AA
ALXN

Altman Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Altman Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,461
Closed -$1.67M – 93
2019
Q4 		$1.67M Sell
15,461
-166
-1% -$17.8K 1.34% 45
2019
Q3 		$1.53M Buy
15,627
+1,873
+14% +$211K 1.3% 48
2019
Q2 		$1.8M Buy
13,754
+203
+1% +$26.2K 1.51% 42
2019
Q1 		$1.83M Buy
13,551
+2,277
+20% +$283K 1.69% 35
2018
Q4 		$1.1M Sell
11,274
-3,305
-23% -$391K 1.2% 43
2018
Q3 		$2.03M Buy
+14,579
New +$1.83M 1.82% 31
2018
Q2 		– Sell
-14,368
Closed -$1.6M – 103
2018
Q1 		$1.6M Buy
14,368
+999
+7% +$119K 1.53% 39
2017
Q4 		$1.6M Buy
+13,369
New +$1.63M 1.39% 39

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Altman Advisors's ALXN Position: Q1 2020 in Review

Altman Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 15,461 shares — an estimated $1.67M sold.

Altman Advisors first reported a position in ALXN in Q4 2017 and held it in 8 quarters. The position peaked at $2.03M in Q3 2018. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Altman Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Altman Advisors sold 15,461 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.67M.
  • Altman Advisors first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 8 quarters.
  • Altman Advisors's Alexion Pharmaceuticals position peaked at $2.03M in Q3 2018.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Altman Advisors's 13F filing for Q1 2020, filed 20 Apr 2020.